Dr. Gustavo Ferrer, President of Aventura Pulmonary Institute, joins Yahoo Finance Live to discuss the latest on the coronavirus pandemic.
Moderna (NASDAQ: MRNA) delivered one piece of bad news to investors a few months ago: Chief medical officer (CMO) Tal Zaks will depart in September. The news came during the initial rollout of Moderna's very first product: its coronavirus vaccine. Moderna allayed investor fears this week, however.
Yahoo Finance’s Alexis Keenan reports the latest on vaccination mandates and bans on vaccination proof.